The Week in Review: October 20 – October 27, 2017

Friday, October 27, 2017 News Recap: Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6. We need to hear your voice by November 8, 2017!  AbbVie’s “GP” combo is pan-genotypic (works for all genotypes). Liver Meeting 2017: I’m A HCV Patient – Show Me What I Need to Know! Why reinvent the wheel? The good folks over at HCV New Drugs have put together this great overview o...

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has announced that its vaccine candidate, TG1050, has demonstrated good efficacy

The Week in Review: August 4 – August 11, 2017

Friday, August 11, 2017 Research & Discoveries Melbourne scientists are creating mini-livers in a dish MELBOURNE scientists are creating mini livers in a dish using a world-first combination of human cells in an ambitious bid to grow liver tissue for transplants. The tiny experimental organs – developed from cells donated by cancer patients – will be used to test drugs and eventually treat disease. Routine hospital tool found to predict poor ...

Melbourne scientists are creating mini-livers in a dish

MELBOURNE scientists are ­creating mini livers in a dish using a world-first combination of human cells in an ambitious bid to grow liver tissue for transplants. The tiny experimental organs — developed from cells donated by cancer patients — will be used to test drugs and eventually treat disease. The O’Brien Institute department of St Vincent’s Institute and St Vincent’s Hospital team has grown liver organoids that are just a few millimetres long. ...

New animal models for hepatitis C could pave the way for a vaccine

They say that an ounce of prevention is worth a pound of cure. In the case of hepatitis C—a disease that affects nearly 71 million people worldwide, causing cirrhosis and liver cancer if left untreated—it might be worth even more. The reason is that the disease shows no outward signs, and more than 80 percent of sufferers go undiagnosed. So while an effective cure does exist, what’s most needed is a vaccine that can prevent infection in the first place.

MicroRNA-34a as a Therapeutic Target in HCC

MicroRNA-34a, one of the most documented tumor suppressor microRNAs, is being evaluated as a potential therapeutic target in hepatocellular carcinoma (HCC) in a study being presented at the 2017 International Liver Congress. Results from a study of microRNA-34a and natural killer (NK) cells suggest that microRNA-34a could have a role in regulating cytotoxicity and development of the effector NK cells and their target cells. Lead author Amira Abdelhamid

Developing HCV Vaccine May Be Possible by Exposing Virus to Immune System Attack

Manipulating the major protein of the hepatitis C virus (HCV) allows the virus to be exposed in a way that the immune system can efficiently detect and attack it. This finding can help improve knowledge behind virus behavior and help in the development of a preventive vaccine for HCV infection. The results were recently published in the journal Hepatology in a study titled “The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neut